Compare Heron Therapeutics Inc (HRTX) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Tesla, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Tesla, Inc. trades at $379.9 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 20124.3× Heron Therapeutics Inc's market cap, and Tesla, Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Tesla, Inc. for 88 Days on average.
| HRTX | TSLA | |
|---|---|---|
Market Cap | $74.04M | $1.49T |
Volume | 3,668,095 | 25,496,215 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $489.88 |
52-Week Low | $0.27 | $298.16 |
Typical Hold Time | 35 Days | 88 Days |
Enterprise Value | $180.78M | $1.46T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Tesla (TSLA) trades at $377.61, down 0.81% amid mixed signals. Technical analysis shows a bullish trend with key support at $375, while fundamentals reveal high valuation multiples (P/E 349.82) despite recent earnings beats. The company faces margin compression with net income declining to $3.79B in 2025. Recent news highlights regulatory approval for driver-assistance software in Europe (Reuters, 2026-04-10) and a potential cheaper EV model launch.
Tesla's investment case balances innovation leadership against valuation concerns. Upside potential exists from autonomous driving advances and energy/robotics growth, but risks include intense EV competition and execution challenges. Analysts maintain a cautious stance with 41% buy ratings and a $441.36 consensus target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
